Article
Selective Immune Silencing by Targeted TGF-β Agonists
2026-01-20
Abstract excerpt
Depletion of pathogenic T and B cells is a pillar of first-line therapies for inflammatory, autoimmune, and transplantation-related immunological diseases. However, concerns about adverse events, safety in immunocompromised patients, and disease relapse from incomplete depletion, limit clinical utility. Here, we exploit the immunosuppressive properties of Transforming growth factor beta (TGF-β), through selective...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 036029b9-9aeb-5a09-8751-c9d5780bed42
- DOI
- 10.64898/2026.01.19.700410
